$MOH
MOLINA HEALTHCARE, INC. Stock $moh

$moh Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000117992918000102 Filed on April 30, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$4.646B	$4.904B
YoY Change	-5.26%	12.92%
Cost Of Revenue	$3.842B	$4.233B
YoY Change	-9.24%	13.94%
Gross Profit	$615.0M	$546.0M
YoY Change	12.64%	25.81%
Gross Profit Margin	13.24%	11.13%
Selling, General & Admin	$531.0M	$550.0M
YoY Change	-3.45%	8.48%
% of Gross Profit	86.34%	100.73%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$37.00M	$49.00M
YoY Change	-24.49%	11.36%
% of Gross Profit	6.02%	8.97%
Operating Expenses	$557.0M	$589.0M
YoY Change	-5.43%	9.28%
Operating Profit	$222.0M	$82.00M
YoY Change	170.73%	-7.87%
Interest Expense	$33.00M	$26.00M
YoY Change	26.92%	4.0%
% of Operating Profit	14.86%	31.71%
Other Income/Expense, Net	-$43.00M	$49.00M
YoY Change	-187.76%	-296.0%
Pretax Income	$179.0M	$131.0M
YoY Change	36.64%	104.69%
Income Tax	$72.00M	$54.00M
% Of Pretax Income	40.22%	41.22%
Net Earnings	$107.0M	$77.00M
YoY Change	38.96%	220.83%
Net Earnings / Revenue	2.3%	1.57%
Basic Earnings Per Share	$1.79	$1.38
Diluted Earnings Per Share	$1.64	$1.37
COMMON SHARES
Basic Shares Outstanding	59.80M shares	56.00M shares
Diluted Shares Outstanding	65.20M shares	56.00M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.173B	$5.254B
YoY Change	17.49%	24.33%
Cash & Equivalents	$3.729B	$3.198B
Short-Term Investments	$2.444B	$2.056B
Other Short-Term Assets	$1.073B	$142.0M
YoY Change	655.63%	-77.71%
Inventory
Prepaid Expenses
Receivables	$950.0M	$1.006B
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.196B	$6.402B
YoY Change	28.02%	11.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$318.0M	$447.0M
YoY Change	-28.86%	6.68%
Goodwill		$620.0M
YoY Change		0.16%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$135.0M	$43.00M
YoY Change	213.95%	16.22%
Total Long-Term Assets	$937.0M	$1.636B
YoY Change	-42.73%	15.29%
TOTAL ASSETS
Total Short-Term Assets	$8.196B	$6.402B
Total Long-Term Assets	$937.0M	$1.636B
Total Assets	$9.133B	$8.038B
YoY Change	13.62%	11.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$713.0M	$438.0M
YoY Change	62.79%	-27.12%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$566.0M	$1.000M
YoY Change	56500.0%	-99.78%
Total Short-Term Liabilities	$6.005B	$4.422B
YoY Change	35.8%	1.03%
LONG-TERM LIABILITIES
Long-Term Debt	$1.318B	$1.653B
YoY Change	-20.27%	42.13%
Other Long-Term Liabilities	$59.00M	$44.00M
YoY Change	34.09%	15.79%
Total Long-Term Liabilities	$1.377B	$1.697B
YoY Change	-18.86%	4365.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.005B	$4.422B
Total Long-Term Liabilities	$1.377B	$1.697B
Total Liabilities	$7.580B	$6.311B
YoY Change	20.11%	12.84%
SHAREHOLDERS EQUITY
Retained Earnings	$412.0M	$887.0M
YoY Change	-53.55%	13.43%
Common Stock	$1.153B	$841.0M
YoY Change	37.1%	4.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.553B	$1.727B
YoY Change
Total Liabilities & Shareholders Equity	$9.133B	$8.038B
YoY Change	13.62%	11.9%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	$107.0M	$77.00M
YoY Change	38.96%	220.83%
Depreciation, Depletion And Amortization	$37.00M	$49.00M
YoY Change	-24.49%	11.36%
Cash From Operating Activities	$394.0M	$719.0M
YoY Change	-45.2%	417.27%
INVESTING ACTIVITIES
Capital Expenditures	$4.000M	$26.00M
YoY Change	-84.62%	-43.48%
Acquisitions		$0.00
YoY Change		-100.0%
Other Investing Activities	$5.000M	$6.000M
YoY Change	-16.67%	-700.0%
Cash From Investing Activities	$145.0M	-$337.0M
YoY Change	-143.03%	7.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$5.000M	-$1.000M
YoY Change	400.0%	-150.0%
NET CHANGE
Cash From Operating Activities	$394.0M	$719.0M
Cash From Investing Activities	$145.0M	-$337.0M
Cash From Financing Activities	-$5.000M	-$1.000M
Net Change In Cash	$534.0M	$381.0M
YoY Change	40.16%	-320.23%
FREE CASH FLOW
Cash From Operating Activities	$394.0M	$719.0M
Capital Expenditures	$4.000M	$26.00M
Free Cash Flow	$390.0M	$693.0M
YoY Change	-43.72%	645.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001179929
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	61685000	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	MOLINA HEALTHCARE INC
CY2018Q1	dei	Trading Symbol TradingSymbol	moh
CY2017Q4	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayable	-912000000	USD
CY2018Q1	moh	Affordable Care Act Premium Stabilization Program Risk Adjustment Receivable Payable AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayable	-1129000000	USD
CY2017Q1	moh	Amortization Of Debt Discount Premium And Sale Leaseback Financing Obligation AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation	8000000	USD
CY2018Q1	moh	Amortization Of Debt Discount Premium And Sale Leaseback Financing Obligation AmortizationOfDebtDiscountPremiumAndSaleLeasebackFinancingObligation	7000000	USD
CY2017Q1	moh	Amount Of Current Year Quality Incentive Premium Revenue Recognized AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized	19000000	USD
CY2018Q1	moh	Amount Of Current Year Quality Incentive Premium Revenue Recognized AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized	24000000	USD
CY2017Q1	moh	Amount Of Quality Incentive Premium Revenue Recognized From Prior Year AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear	5000000	USD
CY2018Q1	moh	Amount Of Quality Incentive Premium Revenue Recognized From Prior Year AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear	11000000	USD
CY2017Q4	moh	Capitation Claims Payable CapitationClaimsPayable	67000000	USD
CY2018Q1	moh	Capitation Claims Payable CapitationClaimsPayable	62000000	USD
CY2017Q1	moh	Changes In Amounts Due To And Due From Affiliates ChangesInAmountsDueToAndDueFromAffiliates	0	USD
CY2018Q1	moh	Changes In Amounts Due To And Due From Affiliates ChangesInAmountsDueToAndDueFromAffiliates	0	USD
CY2017Q1	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	0	USD
CY2018Q1	moh	Health Care Organization Insurer Fee Expense HealthCareOrganizationInsurerFeeExpense	75000000	USD
CY2017Q1	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	0	USD
CY2018Q1	moh	Health Care Organization Insurer Fee Revenue HealthCareOrganizationInsurerFeeRevenue	61000000	USD
CY2017Q1	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	111000000	USD
CY2018Q1	moh	Health Care Organization Premium Tax Revenue HealthCareOrganizationPremiumTaxRevenue	104000000	USD
CY2017Q1	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	373000000	USD
CY2018Q1	moh	Increase Decrease In Medical Premium Liability Due To Agency IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency	172000000	USD
CY2017Q1	moh	Maximum Available Quality Incentive Premium Current Year MaximumAvailableQualityIncentivePremiumCurrentYear	38000000	USD
CY2018Q1	moh	Maximum Available Quality Incentive Premium Current Year MaximumAvailableQualityIncentivePremiumCurrentYear	40000000	USD
CY2017Q4	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	122000000	USD
CY2018Q1	moh	Medical Claims And Benefits Payable MedicalClaimsAndBenefitsPayable	146000000	USD
CY2017Q1	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	-96000000	USD
CY2018Q1	moh	Medical Claims And Benefits Payable Adjustments Change In Provider MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider	45000000	USD
CY2017Q4	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	1542000000	USD
CY2018Q1	moh	Medical Premium Liability Due To Agency MedicalPremiumLiabilityDueToAgency	1714000000	USD
CY2017Q1	moh	Net Income Loss From Continuing Operations Before Equity Method Investments Extraordinary Items Noncontrolling Interest NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest	77000000	USD
CY2018Q1	moh	Net Income Loss From Continuing Operations Before Equity Method Investments Extraordinary Items Noncontrolling Interest NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest	107000000	USD
CY2017Q1	moh	Noncash Restructuring Charges NoncashRestructuringCharges	0	USD
CY2018Q1	moh	Noncash Restructuring Charges NoncashRestructuringCharges	17000000	USD
CY2017Q1	moh	Notes Issued Fair Value Adjustment Increase Decrease NotesIssuedFairValueAdjustmentIncreaseDecrease	0	USD
CY2018Q1	moh	Notes Issued Fair Value Adjustment Increase Decrease NotesIssuedFairValueAdjustmentIncreaseDecrease	-23000000	USD
CY2017Q4	moh	Other Claims Payable OtherClaimsPayable	296000000	USD
CY2018Q1	moh	Other Claims Payable OtherClaimsPayable	248000000	USD
CY2017Q4	moh	Pharmacy Claims Payable PharmacyClaimsPayable	112000000	USD
CY2018Q1	moh	Pharmacy Claims Payable PharmacyClaimsPayable	127000000	USD
CY2017Q1	moh	Policy Holder Benefits Prior Percentage PolicyHolderBenefitsPriorPercentage	0.074
CY2018Q1	moh	Policy Holder Benefits Prior Percentage PolicyHolderBenefitsPriorPercentage	0.110
CY2017Q1	moh	Policy Holder Medical Care Cost Prior Year Percentage PolicyHolderMedicalCareCostPriorYearPercentage	0.009
CY2018Q1	moh	Policy Holder Medical Care Cost Prior Year Percentage PolicyHolderMedicalCareCostPriorYearPercentage	0.014
CY2017Q1	moh	Policy Holder Premium Revenue Prior Year Percentage PolicyHolderPremiumRevenuePriorYearPercentage	0.008
CY2018Q1	moh	Policy Holder Premium Revenue Prior Year Percentage PolicyHolderPremiumRevenuePriorYearPercentage	0.013
CY2017Q1	moh	Premium Tax Expenses PremiumTaxExpenses	111000000	USD
CY2018Q1	moh	Quality Incentive Premium Revenue As A Percentage Of Total Revenue QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue	0.008
CY2018Q1	moh	Premium Tax Expenses PremiumTaxExpenses	104000000	USD
CY2017Q1	moh	Quality Incentive Premium Revenue As A Percentage Of Total Revenue QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue	0.005
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1044000000	USD
CY2017Q1	moh	Quality Incentive Premium Revenue Recognized QualityIncentivePremiumRevenueRecognized	24000000	USD
CY2018Q1	moh	Quality Incentive Premium Revenue Recognized QualityIncentivePremiumRevenueRecognized	35000000	USD
CY2018Q1	moh	Restricted Investments Transferred To Unrestricted During Period RestrictedInvestmentsTransferredToUnrestrictedDuringPeriod	94000000	USD
CY2017Q1	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	17000000	USD
CY2018Q1	moh	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue	37000000	USD
CY2018Q1	moh	Unrecognized Compensation Forfeited Rate UnrecognizedCompensationForfeitedRate	0.097
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	366000000	USD
CY2018Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	713000000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000000	USD
CY2018Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1153000000	USD
CY2017Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	0	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	108000000	USD
CY2017Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8000000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7000000	USD
CY2017Q4	us-gaap	Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries	1691000000	USD
CY2018Q1	us-gaap	Amount Of Restricted Net Assets For Consolidated And Unconsolidated Subsidiaries AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries	1777000000	USD
CY2017Q4	us-gaap	Assets Assets	8471000000	USD
CY2018Q1	us-gaap	Assets Assets	9133000000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	7511000000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	8196000000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2700000000	USD
CY2018Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	2536000000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2693000000	USD
CY2018Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	2521000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	8000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	15000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	3000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	4000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	11000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	1940000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	2001000000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	227000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	226000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost	1000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost	959000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	947000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	1576000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	1573000000	USD
CY2018Q1	us-gaap	Available For Sale Securities Debt Maturities Without Single Maturity Date Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue	2521000000	USD
CY2017Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	719	Security
CY2018Q1	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	915	Security
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	164	Security
CY2018Q1	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	164	Security
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1000000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	1000000	USD
CY2017Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	198000000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	198000000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3198000000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3186000000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3729000000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2912000000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3293000000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3290000000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3824000000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	381000000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	534000000	USD
CY2013Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	53.8475
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	60000000	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62000000	shares
CY2017Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2018Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	0	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	78000000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	100000000	USD
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	4822000000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	4424000000	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	13490236	shares
CY2017Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	4000000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	3000000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	12000000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	12000000	USD
CY2017Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	103000000	USD
CY2018Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	114000000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2018Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	282000000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	404000000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	39000000	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	26000000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	49000000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37000000	USD
CY2017Q4	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	522000000	USD
CY2018Q1	us-gaap	Derivative Assets Current DerivativeAssetsCurrent	585000000	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10000000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	439000000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	352000000	USD
CY2017Q1	us-gaap	Health Care Organization Premium Revenue HealthCareOrganizationPremiumRevenue	4648000000	USD
CY2018Q1	us-gaap	Health Care Organization Premium Revenue HealthCareOrganizationPremiumRevenue	4323000000	USD
CY2017Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2018Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	522000000	USD
CY2018Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	585000000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.38
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.79
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.37
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.64
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	53000000	USD
CY2017Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018Q1	us-gaap	Held To Maturity Securities HeldToMaturitySecurities	120000000	USD
CY2018Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Fair Value HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	3000000	USD
CY2018Q1	us-gaap	Held To Maturity Securities Debt Maturities After One Through Five Years Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount	3000000	USD
CY2018Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Fair Value HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue	117000000	USD
CY2018Q1	us-gaap	Held To Maturity Securities Debt Maturities Within One Year Net Carrying Amount HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount	117000000	USD
CY2018Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	120000000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	131000000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	179000000	USD
CY2017Q1	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2018Q1	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	54000000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	72000000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	50000000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	319000000	USD
CY2017Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	59000000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	78000000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	5000000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	6000000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	146000000	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	130000000	USD
CY2017Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	-3000000	USD
CY2018Q1	us-gaap	Increase Decrease In Health Care Insurance Liabilities IncreaseDecreaseInHealthCareInsuranceLiabilities	-163000000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12000000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	239000000	USD
CY2017Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	32000000	USD
CY2018Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	83000000	USD
CY2017Q1	us-gaap	Increase Decrease Of Restricted Investments IncreaseDecreaseOfRestrictedInvestments	5000000	USD
CY2018Q1	us-gaap	Increase Decrease Of Restricted Investments IncreaseDecreaseOfRestrictedInvestments	0	USD
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q1	us-gaap	Interest Expense InterestExpense	33000000	USD
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	4000000	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2018Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1000000	shares
CY2017Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	255000000	USD
CY2018Q1	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	250000000	USD
CY2017Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	14000000	USD
CY2018Q1	us-gaap	Interest And Dividend Income Operating InterestAndDividendIncomeOperating	24000000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	26000000	USD
CY2017Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	11000000	USD
CY2018Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	9000000	USD
CY2017Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	3000000	USD
CY2018Q1	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	2000000	USD
CY2017Q4	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	0	USD
CY2018Q1	us-gaap	Investments In Affiliates Subsidiaries Associates And Joint Ventures InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures	0	USD
CY2017Q4	us-gaap	Liabilities Liabilities	7134000000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	7580000000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8471000000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9133000000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5557000000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6005000000	USD
CY2016Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1929000000	USD
CY2017Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1926000000	USD
CY2017Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2192000000	USD
CY2018Q1	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	2023000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	2683000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	2498000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1335000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1438000000	USD
CY2017Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	1717000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	1586000000	USD
CY2017Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	4111000000	USD
CY2018Q1	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	3722000000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1516000000	USD
CY2018Q1	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1516000000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	653000000	USD
CY2018Q1	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	566000000	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	2169000000	USD
CY2018Q1	us-gaap	Long Term Debt And Capital Lease Obligations Including Current Maturities LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities	2082000000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1318000000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1318000000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2524000000	USD
CY2018Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2444000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-5000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-337000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	145000000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	719000000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	394000000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	77000000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	107000000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	49000000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-43000000	USD
CY2017Q1	us-gaap	Notes Issued1 NotesIssued1	0	USD
CY2018Q1	us-gaap	Notes Issued1 NotesIssued1	131000000	USD
CY2018Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	3	Segment
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	82000000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	222000000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	141000000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	135000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-7000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	1000000	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-7000000	USD
CY2017Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	61000000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	59000000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	75000000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10000000	USD
CY2017Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3000000	USD
CY2018Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	2000000	USD
CY2017Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	4018000000	USD
CY2018Q1	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	3936000000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	6000000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000000	USD
CY2018Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	23000000	USD
CY2017Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
CY2018Q1	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	5000000	USD
CY2017Q1	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
CY2018Q1	us-gaap	Payments To Acquire Additional Interest In Subsidiaries PaymentsToAcquireAdditionalInterestInSubsidiaries	0	USD
CY2017Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	733000000	USD
CY2018Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	389000000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	26000000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000000	USD
CY2017Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	4111000000	USD
CY2018Q1	us-gaap	Policyholder Benefits And Claims Incurred Health Care PolicyholderBenefitsAndClaimsIncurredHealthCare	3722000000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	871000000	USD
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	239000000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	411000000	USD
CY2017Q1	us-gaap	Proceeds From Dividends Received ProceedsFromDividendsReceived	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1000000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2017Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-2000000	USD
CY2018Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	433000000	USD
CY2018Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	543000000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	342000000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	318000000	USD
CY2018Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	950000000	USD
CY2017Q4	us-gaap	Related Party Transaction Due From To Related Party Current RelatedPartyTransactionDueFromToRelatedPartyCurrent	0	USD
CY2018Q1	us-gaap	Related Party Transaction Due From To Related Party Current RelatedPartyTransactionDueFromToRelatedPartyCurrent	0	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	95000000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	95000000	USD
CY2017Q4	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	169000000	USD
CY2018Q1	us-gaap	Restricted Investments Current RestrictedInvestmentsCurrent	77000000	USD
CY2017Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	119000000	USD
CY2018Q1	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	120000000	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	8000000	USD
CY2017Q1	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2017	us-gaap	Restructuring Costs RestructuringCosts	234000000	USD
CY2018Q1	us-gaap	Restructuring Costs RestructuringCosts	25000000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	48000000	USD
CY2018Q1	us-gaap	Restructuring Reserve RestructuringReserve	32000000	USD
CY2018Q1	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-1000000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	298000000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	412000000	USD
CY2018Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	571000000	USD
CY2017Q1	us-gaap	Revenues Revenues	4904000000	USD
CY2018Q1	us-gaap	Revenues Revenues	4646000000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6000000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6000000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	151965	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	62.99
CY2018Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1000000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	1337000000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	1553000000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1337000000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1553000000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	510253	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	72.46
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	578394	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	740710	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	58.35
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	67.96
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	195972	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	16000000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	15000000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	55.16
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2016Q4	us-gaap	Shares Outstanding SharesOutstanding	56000000	shares
CY2017Q4	us-gaap	Shares Outstanding SharesOutstanding	59000000	shares
CY2018Q1	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Balance StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance	1904000000	USD
CY2018Q1	us-gaap	Statutory Accounting Practices Statutory Capital And Surplus Required StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired	1181000000	USD
CY2017Q1	us-gaap	Stock Issued1 StockIssued1	6000000	USD
CY2018Q1	us-gaap	Stock Issued1 StockIssued1	5000000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	4253000000	USD
CY2018Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	3963000000	USD
CY2017Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-142000000	USD
CY2018Q1	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-241000000	USD
CY2017Q1	us-gaap	Technology Services Costs TechnologyServicesCosts	122000000	USD
CY2018Q1	us-gaap	Technology Services Costs TechnologyServicesCosts	120000000	USD
CY2017Q1	us-gaap	Technology Services Revenue TechnologyServicesRevenue	131000000	USD
CY2018Q1	us-gaap	Technology Services Revenue TechnologyServicesRevenue	134000000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56000000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	65000000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	0	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	1000000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56000000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	60000000	shares
CY2018Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;font-weight:bold;">Presentation and Reclassification</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have reclassified certain amounts in the 2017 consolidated statement of cash flows to conform to the 2018 presentation, relating to the presentation of restricted cash and cash equivalents. The reclassification is a result of our adoption of Accounting Standards Update (ASU) 2016-18,</font><font style="font-family:Arial;font-size:10pt;font-style:italic;"> Restricted Cash </font><font style="font-family:Arial;font-size:10pt;">effective January 1, 2018. See Note </font><font style="font-family:Arial;font-size:10pt;font-style:normal;font-weight:normal;">2</font><font style="font-family:Arial;font-size:10pt;">, “</font><font style="font-family:Arial;font-size:10pt;">Significant Accounting Policies</font><font style="font-family:Arial;font-size:10pt;">,” for further information, including the amount reclassified.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have combined certain line items in the accompanying consolidated balance sheets. For all periods presented, we have combined the presentation of:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes refundable with “Prepaid expenses and other current assets;”</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Income taxes payable with “Accounts payable and accrued liabilities;”</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Goodwill, and intangible assets, net to a single line; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Arial;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Deferred contract costs with “Other assets.”</font></div></td></tr></table></div>
CY2018Q1	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following table provides the details of our medical claims and benefits payable (including amounts payable for the provision of long-term services and supports, or LTSS) as of the dates indicated:</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">March 31, <br clear="none"/>2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31,<br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;font-weight:bold;">(In millions)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fee-for-service claims incurred but not paid (IBNP)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,586</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">1,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Pharmacy payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">112</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Capitation payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">67</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">248</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">296</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,023</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">2,192</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

Files In Submission

Name	View Source	Status
0001179929-18-000102-index-headers.html	Edgar Link	pending
0001179929-18-000102-index.html	Edgar Link	pending
0001179929-18-000102.txt	Edgar Link	pending
0001179929-18-000102-xbrl.zip	Edgar Link	pending
chart-256317090d2f50ba90f.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
moh-03312018x10q.htm	Edgar Link	pending
moh-03312018xex311.htm	Edgar Link	pending
moh-03312018xex312.htm	Edgar Link	pending
moh-03312018xex321.htm	Edgar Link	pending
moh-03312018xex322.htm	Edgar Link	pending
moh-20180331.xml	Edgar Link	completed
moh-20180331.xsd	Edgar Link	pending
moh-20180331_cal.xml	Edgar Link	unprocessable
moh-20180331_def.xml	Edgar Link	unprocessable
moh-20180331_lab.xml	Edgar Link	unprocessable
moh-20180331_pre.xml	Edgar Link	unprocessable
molinalogo2016a26.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MOH
MOLINA HEALTHCARE, INC. Stock $moh

2018 Q1 Form 10-Q Financial Statement

#000117992918000102 Filed on April 30, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH MOLINA HEALTHCARE, INC. Stock $moh

2018 Q1 Form 10-Q Financial Statement

#000117992918000102 Filed on April 30, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MOH
MOLINA HEALTHCARE, INC. Stock $moh